Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1969 3
1970 4
1971 10
1972 14
1973 22
1974 21
1975 31
1976 33
1977 30
1978 28
1979 22
1980 15
1981 16
1982 14
1983 17
1984 15
1985 9
1986 22
1987 8
1988 15
1989 17
1990 11
1991 14
1992 21
1993 23
1994 18
1995 16
1996 18
1997 14
1998 16
1999 27
2000 24
2001 18
2002 24
2003 25
2004 30
2005 27
2006 40
2007 42
2008 50
2009 47
2010 50
2011 47
2012 56
2013 61
2014 73
2015 69
2016 71
2017 67
2018 83
2019 88
2020 112
2021 124
2022 110
2023 92
2024 97
2025 110
2026 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,998 results

Results by year

Filters applied: . Clear all
Page 1
Intraaortic balloon support for myocardial infarction with cardiogenic shock.
Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Böhm M, Ebelt H, Schneider S, Schuler G, Werdan K; IABP-SHOCK II Trial Investigators. Thiele H, et al. N Engl J Med. 2012 Oct 4;367(14):1287-96. doi: 10.1056/NEJMoa1208410. Epub 2012 Aug 26. N Engl J Med. 2012. PMID: 22920912 Free article. Clinical Trial.
BACKGROUND: In current international guidelines, intraaortic balloon counterpulsation is considered to be a class I treatment for cardiogenic shock complicating acute myocardial infarction. ...METHODS: In this randomized, prospective, ope …
BACKGROUND: In current international guidelines, intraaortic balloon counterpulsation is considered to be a class I treatment …
Management of cardiogenic shock complicating myocardial infarction: an update 2019.
Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Thiele H, et al. Eur Heart J. 2019 Aug 21;40(32):2671-2683. doi: 10.1093/eurheartj/ehz363. Eur Heart J. 2019. PMID: 31274157 Review.
Cardiogenic shock (CS) remains the most common cause of death in patients admitted with acute myocardial infarction (AMI) and mortality remained nearly unchanged in the range of 40-50% during the last two decades. ...However, there is only limited evid …
Cardiogenic shock (CS) remains the most common cause of death in patients admitted with acute myocardial infarction …
A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction.
Seyfarth M, Sibbing D, Bauer I, Fröhlich G, Bott-Flügel L, Byrne R, Dirschinger J, Kastrati A, Schömig A. Seyfarth M, et al. J Am Coll Cardiol. 2008 Nov 4;52(19):1584-8. doi: 10.1016/j.jacc.2008.05.065. J Am Coll Cardiol. 2008. PMID: 19007597 Free article. Clinical Trial.
OBJECTIVES: The aim of this study was to test whether the left ventricular assist device (LVAD) Impella LP2.5 (Abiomed Europe GmbH, Aachen, Germany) provides superior hemodynamic support compared with the intra-aortic balloon pump (IABP). BACKGROUND: Cardiogenic …
OBJECTIVES: The aim of this study was to test whether the left ventricular assist device (LVAD) Impella LP2.5 (Abiomed Europe GmbH, Aachen, …
Management of cardiogenic shock.
Thiele H, de Waha-Thiele S, Freund A, Zeymer U, Desch S, Fitzgerald S. Thiele H, et al. EuroIntervention. 2021 Aug 27;17(6):451-465. doi: 10.4244/EIJ-D-20-01296. EuroIntervention. 2021. PMID: 34413010 Free PMC article. Review.
Despite the rapidly evolving evidence base in modern cardiology, progress in the area of cardiogenic shock remains slow, with short-term mortality still reaching 40-50%, relatively unchanged in recent years. ...This updated 2020 review will outline the management of …
Despite the rapidly evolving evidence base in modern cardiology, progress in the area of cardiogenic shock remains slow, with …
Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction.
Ouweneel DM, Eriksen E, Sjauw KD, van Dongen IM, Hirsch A, Packer EJ, Vis MM, Wykrzykowska JJ, Koch KT, Baan J, de Winter RJ, Piek JJ, Lagrand WK, de Mol BA, Tijssen JG, Henriques JP. Ouweneel DM, et al. J Am Coll Cardiol. 2017 Jan 24;69(3):278-287. doi: 10.1016/j.jacc.2016.10.022. Epub 2016 Oct 31. J Am Coll Cardiol. 2017. PMID: 27810347 Free article. Clinical Trial.
BACKGROUND: Despite advances in treatment, mortality in acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) remains high. Short-term mechanical circulatory support devices acutely improve hemodynamic conditions. OBJECTIVES: The aim …
BACKGROUND: Despite advances in treatment, mortality in acute myocardial infarction (AMI) complicated by cardiogenic …
Intraaortic Balloon Pump Counterpulsation, Part I: History, Technical Aspects, Physiologic Effects, Contraindications, Medical Applications/Outcomes.
González LS, Chaney MA. González LS, et al. Anesth Analg. 2020 Sep;131(3):776-791. doi: 10.1213/ANE.0000000000004954. Anesth Analg. 2020. PMID: 32590485 Review.
Intraaortic balloon pump counterpulsation is the most common form of mechanical circulatory support used in patients with myocardial ischemia and cardiogenic shock. The physiologic principles of counterpulsation include diastolic augmentation of …
Intraaortic balloon pump counterpulsation is the most common form of mechanical circulatory support used in patients with m …
Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.
Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Hochman JS, et al. N Engl J Med. 1999 Aug 26;341(9):625-34. doi: 10.1056/NEJM199908263410901. N Engl J Med. 1999. PMID: 10460813 Free article. Clinical Trial.
BACKGROUND: The leading cause of death in patients hospitalized for acute myocardial infarction is cardiogenic shock. We conducted a randomized trial to evaluate early revascularization in patients with cardiogenic shock. ...Early revascu …
BACKGROUND: The leading cause of death in patients hospitalized for acute myocardial infarction is cardiogenic shock …
Intraaortic balloon pump in patients with cardiogenic shock complicating myocardial infarction: a systematic review and meta-analysis of randomized trials.
Altayyar S, Al-Omari A, Alqahtani AM, Rochwerg B, Alnasser S, Alqahtani Z, Fox-Robichaud A, Alhazzani W. Altayyar S, et al. Pol Arch Med Wewn. 2015;125(3):181-90. doi: 10.20452/pamw.2713. Epub 2015 Feb 20. Pol Arch Med Wewn. 2015. PMID: 25698226 Free article.
INTRODUCTION: Cardiogenic shock is associated with significant mortality, particularly when caused by myocardial infarction. Intraaortic balloon pump (IABP) is the primary hemodynamic adjunct in patients with cardiogenic shock …
INTRODUCTION: Cardiogenic shock is associated with significant mortality, particularly when caused by myocardial inf …
Cardiogenic shock.
Topalian S, Ginsberg F, Parrillo JE. Topalian S, et al. Crit Care Med. 2008 Jan;36(1 Suppl):S66-74. doi: 10.1097/01.CCM.0000296268.57993.90. Crit Care Med. 2008. PMID: 18158480 Review.
Cardiogenic shock is the most common cause of death in patients hospitalized with acute myocardial infarction and is associated with a poor prognosis. ...To decrease the incidence of cardiogenic shock, public education regarding early pre …
Cardiogenic shock is the most common cause of death in patients hospitalized with acute myocardial infarction an …
Cardiogenic shock.
Cooper HA, Panza JA. Cooper HA, et al. Cardiol Clin. 2013 Nov;31(4):567-80, viii. doi: 10.1016/j.ccl.2013.07.009. Epub 2013 Sep 20. Cardiol Clin. 2013. PMID: 24188221 Review.
Cardiogenic shock (CS) is a condition in which a marked reduction in cardiac output and inadequate end-organ perfusion results from an array of cardiac insults, the most common of which is acute myocardial infarction. CS is a systemic disease involving …
Cardiogenic shock (CS) is a condition in which a marked reduction in cardiac output and inadequate end-organ perfusion results …
1,998 results